MedTrace Logo

Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Peanut Allergy

NCT02920021 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-07-27

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine etokimab safety, tolerability and activity in adult participants with peanut allergy.

Conditions

Interventions

DRUG

Etokimab

Humanized monoclonal antibody, administered by intravenous infusion

DRUG

Placebo

Administered by intravenous infusion

Sponsors & Collaborators

  • AnaptysBio, Inc.

    lead INDUSTRY

Principal Investigators

  • Bruce Randazzo, MD · AnaptysBio, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-26
Primary Completion
2018-03-30
Completion
2018-03-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02920021 on ClinicalTrials.gov